This SR highlights the lack of long-term RCTs reporting final height data and other important qualitative outcomes , such as quality of life .
ABSTRACT Genotropin ( somatropin ) is licensed for the treatment of children with growth hormone deficiency , Prader-Willi syndrome , Turner syndrome , chronic renal insufficiency and in children born small for gestational age .
This systematic review ( SR ) evaluated the clinical efficacy and effectiveness of Genotropin in these conditions to inform a NICE Technology Appraisal of growth hormone for the treatment of growth failure in children .
Quality of life and psychological well-being in GH-treated, adult PWS patients: a longitudinal study.
BACKGROUND Prader-Willi syndrome ( PWS ) is a congenital alteration of chromosome pair 15 . It is characterized by short stature , muscular hypotonia , hyperphagia , obesity , behavioural and emotional disturbances , hypogonadism and partial Growth Hormone ( GH ) deficiency . The aim of this study was to assess the long-term effect of GH treatment on the psychological well-being and Quality of Life ( QoL ) in an adult PWS group . METHODS A total of 13 PWS patients , their diagnosis confirmed by genetic tests , and their parents were recruited for this study . The participants were administered the 36-Items Short Form Health Survey ( SF-36 ) and the Psychological General Well-Being Index ( PGWBI ) , for the assessment of QoL and psychological well-being , at the beginning of GH treatment , and at following intervals of 6 , 12 and 24 months . Modified versions of the same question naires were given to the parents . RESULTS Significant improvement with respect to the baseline was found , on both scales , in the evaluation of both physical and psychological well-being , although the parents ' evaluation was less optimistic than that of the patients . CONCLUSION Our findings suggest that the amelioration of QoL and psychological status is sustained in patients who continue GH treatment
This SR highlights the lack of long-term RCTs reporting final height data and other important qualitative outcomes , such as quality of life .
ABSTRACT Genotropin ( somatropin ) is licensed for the treatment of children with growth hormone deficiency , Prader-Willi syndrome , Turner syndrome , chronic renal insufficiency and in children born small for gestational age .
This systematic review ( SR ) evaluated the clinical efficacy and effectiveness of Genotropin in these conditions to inform a NICE Technology Appraisal of growth hormone for the treatment of growth failure in children .